Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles

Virology Journal

Martin Tolstrup²  Mogens Duch¹  Lars Ostergaard²  Damian FJ Purcell³  Robert J Center³  Finn S Pedersen¹  Shervin Bahrami⁴  Jesper Melchjorsen²  Adam Wheatley³  Tea Kirkegaard² 

[1] Interdisciplinary Nanoscience Center, University of Aarhus, DK-8000 Aarhus, Denmark;Department of Infectious Diseases, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark;Department of Microbiology and Immunology, University of Melbourne, Parkville 3010, VIC, Australia;SKAU Vaccines, INCUBA Science Park, Brendstrupgaardsvej, DK-8200 Aarhus N, Denmark

关键词: immunity;    γ-retroviruses;    Virus-like particles;    HIV-1 envelope protein;   

Others  :  1156378
DOI  :  10.1186/1743-422X-8-381

 received in 2011-04-12, accepted in 2011-08-01,  发布年份 2011

【 摘 要 】

This study evaluates the immunogenicity of the HIV envelope protein (env) in mice presented either attached to γ-retroviral virus-like-particles (VLPs), associated with cell-derived microsomes or as solubilized recombinant protein (gp160). The magnitude and polyfunctionality of the cellular immune response was enhanced when delivering HIV env in the VLP or microsome form compared to recombinant gp160. Humoral responses measured by antibody titres were comparable across the groups and low levels of antibody neutralization were observed. Lastly, we identified stronger IgG2a class switching in the two particle-delivered antigen vaccinations modalities compared to recombinant gp160.

【 授权许可】

   
2011 Kirkegaard et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Johnson PR, Schnepp BC, Zhang J, et al.: Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009, 15:901-906.
• [2]Mascola JR, Stiegler G, VanCott TC, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207-210.
• [3]Zhu P, Liu J, Bess J, et al.: Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441:847-852.
• [4]Montefiori DC, Mascola JR: Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr Opin HIV AIDS 2009, 4:347-351.
• [5]Hoxie JA: Toward an antibody-based HIV-1 vaccine. Annu Rev Med 2010, 61:135-152.
• [6]Crooks ET, Moore PL, Franti M, et al.: A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 2007, 366:245-262.
• [7]McBurney SP, Young KR, Ross TM: Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 2007, 358:334-346.
• [8]Quan FS, Sailaja G, Skountzou I, et al.: Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine 2007, 25:3841-3850.
• [9]Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM: Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 2005, 79:7059-7067.
• [10]Hammonds J, Chen X, Fouts T, DeVico A, Montefiori D, Spearman P: Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J Virol 2005, 79:14804-14814.
• [11]Bellier B, Huret C, Miyalou M, et al.: DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine 2009, 27:5772-5780.
• [12]Mammano F, Salvatori F, Indraccolo S, De Rossi A, Chieco-Bianchi L, Göttlinger HG: Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells. J Virol 1997, 71:3341-3345.
• [13]Schnierle BS, Stitz J, Bosch V, et al.: Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci USA 1997, 94:8640-8645.
• [14]Byland R, Vance PJ, Hoxie JA, Marsh M: A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein. Mol Biol Cell 2007, 18:414-425.
• [15]Devitt G, Emerson V, Holtkotte D, Pfeiffer T, Pisch T, Bosch V: Incorporation of chimeric HIV-SIV-Env and modified HIV-Env proteins into HIV pseudovirions. Virology 2007, 361:465-471.
• [16]Kim YB, Lee MK, Han DP, Cho MW: Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain. AIDS Res Hum Retroviruses 2001, 17:1715-1724.
• [17]Kalyanaraman VS, Rodriguez V, Veronese F, et al.: Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1990, 6:371-380.
• [18]Morita S, Kojima T, Kitamura T: Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 2000, 7:1063-1066.
• [19]Tolstrup M, Selzer-Plön J, Laursen AL, et al.: Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137 K). AIDS 2007, 21:519-521.
• [20]Cantin R, Diou J, Bélanger D, Tremblay AM, Gilbert C: Discrimination between exosomes and HIV-1: purification of both vesicles from cell-free supernatants. J Immunol Methods 2008, 338:21-30.
• [21]Center RJ, Wheatley AK, Campbell SM, et al.: Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine 2009, 27:6605-6612.
• [22]Leclerc C, Dériaud E, Rojas M, Whalen RG: The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol 1997, 179:97-106.